Updating exposure assessment for skin sensitization quantitative risk assessment for fragrance materials.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 29 06 2020
revised: 02 10 2020
accepted: 09 10 2020
pubmed: 20 10 2020
medline: 29 7 2021
entrez: 19 10 2020
Statut: ppublish

Résumé

In 2008, a proposal for assessing the risk of induction of skin sensitization to fragrance materials Quantitative Risk Assessment 1 (QRA1) was published. This was implemented for setting maximum limits for fragrance materials in consumer products. However, there was no formal validation or empirical verification after implementation. Additionally, concerns remained that QRA1 did not incorporate aggregate exposure from multiple product use and included assumptions, e.g. safety assessment factors (SAFs), that had not been critically reviewed. Accordingly, a review was undertaken, including detailed re-evaluation of each SAF together with development of an approach for estimating aggregate exposure of the skin to a potential fragrance allergen. This revision of QRA1, termed QRA2, provides an improved method for establishing safe levels for sensitizing fragrance materials in multiple products to limit the risk of induction of contact allergy. The use of alternative non-animal methods is not within the scope of this paper. Ultimately, only longitudinal clinical studies can verify the utility of QRA2 as a tool for the prevention of contact allergy to fragrance materials.

Identifiants

pubmed: 33075411
pii: S0273-2300(20)30231-2
doi: 10.1016/j.yrtph.2020.104805
pii:
doi:

Substances chimiques

Allergens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104805

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Anne Marie Api (AM)

Research Institute for Fragrance Materials, Inc., Woodcliff Lake, NJ, USA. Electronic address: amapi@rifm.org.

David Basketter (D)

Consultant, DABMEB Consultancy Ltd., Sharnbrook, UK.

James Bridges (J)

Member IDEA Supervisory Group, University of Surrey, Guildford, UK.

Peter Cadby (P)

Consultant, Geneva, Switzerland.

Graham Ellis (G)

Firmenich SA, 1 Route des Jeunes, Geneva, Switzerland.

Nicola Gilmour (N)

Unilever Safety & Environmental Assurance Centre, Sharnbrook, UK.

Helmut Greim (H)

Member IDEA Supervisory Group, Technical University of Munich, Germany.

Peter Griem (P)

Symrise AG, Holzminden, Germany.

Petra Kern (P)

NV Procter & Gamble Services Company SA, Strombeek-Bever, Belgium.

Alain Khaiat (A)

Member IDEA Supervisory Group, Cosmetics Consultant, Singapore.

John O'Brien (J)

Creme Global, Dublin, Ireland.

Thomas Rustemeyer (T)

Member IDEA Supervisory Group, VU Amsterdam, Netherlands.

Cindy Ryan (C)

The Procter & Gamble Company, Mason, OH, USA.

Bob Safford (B)

Consultant, B-Safe Toxicology Consulting, Rushden, UK.

Benjamin Smith (B)

Innovations in Food and Chemical Safety Programme, Singapore Institute of Food & Biotechnology Innovation, Agency for Science, Technology & Research, Singapore; School of Chemical & Biomedical Engineering, Nanyang Technological University, Singapore.

Matthias Vey (M)

International Fragrance Association, Brussels, Belgium.

Ian R White (IR)

Member IDEA Supervisory Group, St. John's Institute of Dermatology, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH